Print this page
Multiple Myeloma
-
Impact of Early Radiation Oncology Involvement as Part of a Multidisciplinary Palliative Care Team on Quality of Life Among Diverse Patients with Advanced/Metastatic Malignancies.
Protocol: 002168Principal Investigator:
- Malcolm Mattes
Applicable Disease Sites: Any Site -
The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization.
Protocol: 011910Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Bones and Joints
Ill-Defined Sites
Multiple Myeloma -
Machine Learning-based High-throughput and Integrative Immunological Synapse Quality Evaluation As a Composite Biomarker for Predicting CAR Therapy Efficacy in Immuno-Oncology.
Protocol: 012108Principal Investigator:
- Yun Kyoung Tiger
Applicable Disease Sites: Hodgkin's Lymphoma
Multiple Myeloma
Non-Hodgkin's Lymphoma -
A Long-Term Study for Participants Previously Treated With Ciltacabtagene Autoleucel.
Protocol: 012204Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Multiple Myeloma -
Phase 1/2 Study of Linvoseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma (Linker-MM4 Study).
Protocol: 012310Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
Testing of Immune Synapse Characteristics During Therapy of Multiple Myeloma
Protocol: 012322Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma.
Protocol: 012402Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma.
Protocol: 012405Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1/2 Study of ABBV-383 in Combination with Anti-Myeloma Agents for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Protocol: 012502Principal Investigator:
- Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP- 5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL) Rearrangement or Nucleophosmin 1 (NPM1) Mutation.
Protocol: 022303Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia.
Protocol: 022404-MM1OA-EA0Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial).
Protocol: 022404-MM1YA-CTGPrincipal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia.
Protocol: 022404-MM1YA-S01Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other